protopic
leo pharma a/s - takrólímus - dermatitis, atópísk - aðrar húðsjúkdómar - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. koma fjórir eða meira sinnum á ári) sem hafa haft fyrstu viðbrögð við sex vikur meðferð tvisvar á dag takrólímus smyrslið (sár ruddi, næstum ruddi eða dálítið áhrifum).
vectibix
amgen europe b.v. - panitumumab - litlaræxli - Æxlishemjandi lyf - vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc): , in first-line in combination with folfox or folfiri. , í öðru-línu í ásamt folfiri fyrir sjúklinga sem hafa fengið fyrsta lína fluoropyrimidine byggir lyfjameðferð (án irínótecan). , eitt og sér eftir bilun fluoropyrimidine-, oxaliplatin-og irínótecan-inniheldur lyfjameðferð meðferð.
sogroya
novo nordisk a/s - somapacitan - vöxtur - hinsveiflur og heilahimnubólur og hliðstæður - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).
kinpeygo
stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheals, þarma bólgueyðandi / antiinfective lyfjum - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.
eplerenon bluefish filmuhúðuð tafla 25 mg
bluefish pharmaceuticals ab - eplerenonum inn - filmuhúðuð tafla - 25 mg
eplerenon krka filmuhúðuð tafla 50 mg
krka, d.d., novo mesto - eplerenonum inn - filmuhúðuð tafla - 50 mg
tenutex húðfleyti 20 mg/g + 225 mg/g
bioglan ab - disulfiramum inn; benzylis benzoas - húðfleyti - 20 mg/g + 225 mg/g
heparin leo (heparin leo) stungulyf, lausn 5000 a.e./ml
leo pharma a/s* - heparinum natricum inn - stungulyf, lausn - 5000 a.e./ml
prednisolon actavis tafla 10 mg
actavis group ptc ehf. - prednisolone - tafla - 10 mg
exemestan actavis filmuhúðuð tafla 25 mg
actavis group ptc ehf. - exemestanum inn - filmuhúðuð tafla - 25 mg